What do systematic reviews say?

Intervention not reported

The review found no eligible studies for this question.

• Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 2: PLD alone vs other conventional chemotherapy

The review found no eligible studies for this question.

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Immune checkpoint inhibitors vs any first‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 393 participants
  Moderate

Immune checkpoint inhibitors vs any second‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 727 participants
  Low

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

• Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 5 participants
  Low

Degarelix vs standard androgen suppression therapy

• Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 2887 participants
  Moderate

Foam vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser therapy vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 691 participants
  Low

Sunitinib vs IFN‐α (targeted agent versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 544 participants
  Moderate

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 401 participants
  Low

Sunitinib vs atezolizumab (targeted therapy versus immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 157 participants
  Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 394 participants
  Low

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 460 participants
  Moderate

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sodium thiosulfate vs no otoprotective intervention

The review found no eligible studies for this question.

• Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Amifostine vs no otoprotective intervention

The review found no eligible studies for this question.

• Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

The review found no eligible studies for this question.

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hyperbaric oxygen vs air breathing

The review found no eligible studies for this question.

• Hyperbaric oxygenation for tumour sensitisation to radiotherapy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found